# A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

> **NCT03773978** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 220 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03773978
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-17
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-01-26
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2022-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03773978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03773978, "A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03773978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*